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Background
There has been a recent rise in antidepressant prescriptions.
After the episode for which it was prescribed, the patient should
ideally be supported in withdrawing the medication. There is
increasing evidence for withdrawal symptoms (sometimes called
discontinuation symptoms) occurring on ceasing treatment,
sometimes having severe or prolonged effects.
Aims
To identify and compare current knowledge, attitudes and
practices of general practitioners (GPs) and psychiatrists in
Cornwall, UK, concerning antidepressant withdrawal symptoms.
Method
Questions about withdrawal symptoms and management were
asked of GPs and psychiatrists in a multiple-choice cross-sec-
tional study co-designed with a lived experience expert.
Results
Psychiatrists thought that withdrawal symptoms were more
severe than GPs did (P = 0.003); 53% (22/42) of GPs and 69%
(18/26) of psychiatrists thought that withdrawal symptoms
typically last between 1 and 4 weeks, although there was a wide
range of answers given; 35% (9/26) of psychiatrists but no GPs
identified a pharmacist as someone they may use to help man-
age antidepressant withdrawal. About three-quarters of
respondents claimed they usually or always informed patients of
potential withdrawal symptoms when they started a patient on
antidepressants, but patient surveys say only 1% are warned.
Conclusions
Psychiatrists and GPs need to effectively warn patients of
potential withdrawal effects. Community pharmacists might be
useful in supporting GP-managed antidepressant withdrawal.
The wide variation in responses to most questions posed to
participants reflects the variation in results of research on the
topic. This highlights a need for more reproducible studies to be
carried out on antidepressant withdrawal, which could inform
future guidelines.
Keywords
Antidepressants; withdrawal side-effects; public mental health;
public opinion.
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Antidepressant use has increased in recent years, with the number
of prescriptions in England doubling in the past decade from the
number in the mid-2000s.1 In 2018 the number of antidepressant
prescriptions in England was 70.9 million.2 While antidepressants
are generally considered beneficial to many of the people taking
them, there are risks of withdrawal symptoms when patients
later discontinue treatment. These are also known as discontinu-
ation symptoms. A range of problems varying in intensity and dur-
ation have been reported, including increased anxiety, flu-like
symptoms, insomnia, nausea, imbalance, sensory disturbances,
hyperarousal, ‘brain zaps’, depersonalisation and sensory distur-
bances.1,3,4 The UK’s National Institute for Health and Care
Excellence (NICE) guidelines have been recently updated and
state that ‘whilst the withdrawal symptoms which arise when stop-
ping or reducing antidepressants can be mild and self-limiting,
there is substantial variation in people’s experience, with symp-
toms lasting much longer (sometimes months or more) and
being more severe for some patients’.5 A recent all-party parlia-
mentary group concluded that ‘It is incorrect to view antidepres-
sant withdrawal as largely mild, self-limiting and of short
duration’.6 This evidence suggests that withdrawal symptoms
could be worse than those identified by NICE. The Royal
College of Psychiatrists says that the potential benefits and
harms of antidepressants, including withdrawal, should be dis-
cussed with the patient.7 The exact pathophysiology of withdrawal
symptoms is unclear, but previous studies have hypothesised that
they are a response to long-term physiological adaption of cerebral
neural systems, or that they could be caused by a rapid decrease in
serotonin availability when the treatment ends abruptly.3
Issues with antidepressant withdrawal symptoms
There are various confounders surrounding the issue of withdrawal
symptom reporting. For example, withdrawal symptoms can be
mistaken for relapse, prompting re-starting of the antidepressant
or changing to an alternative one, extending antidepressant use.1
In terms of patient perspective, fewer than 2% of antidepressant
users recall being told by the prescriber about any withdrawal
effects, or potential difficulties coming off the drugs.1 Patients
who reported lack of knowledge of withdrawal symptoms also
experienced greater adverse effects during withdrawal.3 Another
poorly researched concept is the ‘nocebo’ effect – the expectation
of feeling worse on discontinuation.1 Withdrawal effects can vary
depending on the drug. For example, they may occur less frequently
and less severely with longer-acting agents such as fluoxetine,3,8
giving rise to the option of switching to fluoxetine before stopping
antidepressants completely, to potentially reduce withdrawal
effects.8 Generally, selective serotonin reuptake inhibitors (SSRIs)
with a shorter half-life seem to have worse withdrawal effects.3
For example, paroxetine has been found to have a higher incidence
of antidepressant withdrawal when compared with fluoxetine and
sertraline.8,9 It is not known exactly why this is the case but with-
drawal severity is believed to depend on the elimination half-life
of the drug and the patient’s rate of metabolism.3
Alleviating antidepressant withdrawal symptoms
Approaches have been suggested to reduce withdrawal symptoms,
but there is conflicting evidence. One example is using cognitive–
behavioural therapy (CBT) during withdrawal to promote
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understanding that any symptoms are temporary and due to with-
drawal, rather than indicating an inability to cope without the medi-
cation.3 Patients who experienced worse adverse symptoms when
commencing antidepressant treatment were more likely to suffer
withdrawal symptoms; therefore, identifying these people could
allow closer monitoring during withdrawal.10
Overall, literature about antidepressant withdrawal seems to
differ from the NICE guidelines particularly in that there could be
more advice about alleviating symptoms. There is little research
exploring what professionals do in practice to inform and manage
withdrawal symptoms, which in turn can influence patient outcomes.
To our knowledge, no study has systematically examined and
compared how different groups of prescribers perceive withdrawal
effects of antidepressants. Knowledge and understanding of
general practitioners’ (GPs’) and psychiatrists’ attitudes towards
withdrawal symptoms may allow identification of gaps in guide-
lines, policy or training.
Aims
This study aimed to identify current knowledge, attitudes and prac-
tices of GPs and psychiatrists in Cornwall, UK (population: 538 000)
concerning antidepressant withdrawal symptoms.
Method
We completed a cross-sectional study of the opinions and percep-
tions of GPs and psychiatrists. The two groups were asked to com-
plete a very similar questionnaire, with the GP survey consisting of
nine questions and the psychiatrists’ survey having 14 questions
(Supplementary information 1 and 2, available at https://doi.org/
10.1192/bjo.2020.48). The questionnaires contained questions asses-
sing perceptions about, and approach to, antidepressant withdrawal.
Both surveys consisted of a mix of questions with predetermined
answers, questions requiring the answer to be entered, and one ques-
tion that allowed for free-text comments. The questionnaires were
constructed by the authors on the basis of a review of the literature
and were co-designed with a lived experience expert. Some limited
demographic details were collected from the psychiatrists, although
for both groups the survey was anonymous. The method of delivery
of the questionnaire differed for the two groups. An edited summary
of the questions is included in the Appendix.
GPs
Across Cornwall, locality-based prescribing meetings are held in the
North, Central and West GP localities of NHS Kernow, the clinical
commissioning group (CCG) for the county, four times a year.
These 12 meetings a year, organised by the CCG’s Medicines
Optimisation Team, are intended to have a focus on clinical pre-
scribing and medicines optimisation. A GP prescribing lead from
each primary care practice of the county is invited to attend these
meetings and disseminate the learning to other GPs within their
own practice. The questionnaire was handed out to GPs attending
the winter 2019 meetings.
Psychiatrists
For the psychiatrists, an introductory email and electronic link to
the survey were emailed out to all 60 practitioners employed by
Cornwall Partnership NHS Foundation Trust purposively selected
through established contacts. A reminder email was sent 1 week
later. Ten of these were psychiatric trainees (core training years
CT1–3) and 50 were in senior posts (registrars in specialty training
years ST4–6, consultants and associate specialists). For simplicity,
this paper will refer to this group as ‘psychiatrists’ and the group
from GP meetings as ‘GPs’.
Analysis of data was performed using Microsoft Excel (365
version, 2004). Descriptive statistics were used to describe and sum-
marise the data highlighting the main elements of the study. Mann–
Whitney U-tests were also used to evaluate whether there was any
difference in responses between the two groups. IBM SPSS
Statistics 26 forWindows was used to carry out these statistical tests.
Ethics and participation consent
No ethical permission was required as this was a study to evaluate
knowledge and attitudes as part of a service evaluation.
Furthermore, it involved a group of medical practitioners where
consent was implicit by participation. All participants were
advised at the start of the study that participation was voluntary
and their replies, i.e. data, would be anonymised and analysed.
We also used the NHS Research Authority tool (http://www.hra-
decisiontools.org.uk/research/index.html), which helped confirm
that no ethics approval was needed for this project
(Supplementary information 3).
Results
There are 60 GP surgeries (primary care centres) within NHS
Kernow CCG. The three meetings in winter 2019 were attended
by a total of 53 GPs (88% attendance), with completed question-
naires returned by 42 (79%) of the attendees. No other GP charac-
teristics were recorded. Of the 60 doctors and associate specialists
working for psychiatry services in Cornwall Partnership NHS
Foundation Trust, 26 responded to the electronic survey (43%
response rate): consultants (n = 17); associate specialists (n = 2);
speciality doctor (n = 1); ST4–6 trainee (n = 1); CT1–3 trainees
(n = 4); 1 respondent did not state their level of experience so it is
unknown. A range of specialties were represented: general adult
psychiatry (n = 12); child and adolescent psychiatry (n = 7);
complex care and dementia psychiatry (n = 4); psychiatry of intel-
lectual disability (n = 2); 1 respondent did not give their specialty.
For the purposes of this paper, we will focus on the answers to
the questions concerning duration of withdrawal symptoms, sever-
ity of withdrawal symptoms, their frequency of occurrence, what
might prompt stopping antidepressants, what proportion of
patients approached the respondents about stopping their antide-
pressants, how respondents would withdraw them, who they
might work with and how often they discuss potential withdrawal
symptoms before commencing treatment.
When asked how long they believe withdrawal symptoms typic-
ally last for, 53% (22/42) of the GPs and 69% (18/26) of the psychia-
trists perceived the duration to be between 1 and 4 weeks (Table 1).
There was no statistical difference between the two groups (P =
0.979).
Table 1 Perception of the typical duration of withdrawal symptoms, as







No withdrawal symptoms 0 (0%) 0 (0%)
1–3 days 2 (5%) 1 (4%)
4–6 days 4 (10%) 1 (4%)
1–2 weeks 10 (24%) 7 (27%)
2–4 weeks 12 (29%) 11 (42%)
1–2 months 9 (21%) 3 (12%)
2–4 months 4 (10%) 1 (4%)
4–6 months 2 (5%) 1 (4%)
Over 6 months 0 (0%) 1 (4%)
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As regards the severity of withdrawal symptoms, on average (on
a scale of 1 to 10, where 1 is no negative effect at all and 10 is life-
threatening) the mean value for the GPs’ responses was 3.8 (s.d. =
1.3), although the range was 1–6. The mean value for psychiatrists
was 5 (s.d. = 1.7) and the range was 1–8. On the e-questionnaire
completed by the psychiatrists, they were only able to select
whole-number answers. On the paper survey that was completed
by the GPs, some chose to give ranges. For the purposes of analysis,
the midpoint of the range they gave was used. The results for this
question can be seen in Fig. 1. There is a statistical difference
between the two groups for this question (P = 0.003), with the psy-
chiatrists perceiving more severe withdrawal symptoms than the
GPs.
The proportion of people believed to be affected by withdrawal
symptoms when stopping antidepressants is shown in Table 2, with
just under half of our GP respondents (45%) and just under one-
third of the psychiatrists (31%) perceiving that 21–40% of patients
are affected when withdrawing antidepressants. There is no statis-
tical difference between the two groups (P = 0.606).
When asked what might prompt them to discuss stopping anti-
depressants with a patient (such as any particular indications or
time periods), five main themes emerged for each group, as
shown in Table 3.
All but four of the GPs provided free-text answers to a question
about the three main concerns that might prompt them to discuss
with a patient whether to stop antidepressants (such as any particular
indications or time periods). The main headings are as follows: dur-
ation of treatment, for example after 6 months or after 1 year, was
mentioned by 26 GPs; 9 GPs said that the patient asking to end treat-
ment might act as a prompt; treatment side-effects and a routine
medication review were each mentioned by 8 GPs; and noting an
improvement in the patient’s symptoms was cited by 7 GPs.
All the psychiatrists provided free-text answers to this question.
The main headings are as follows: side-effects (21 responses); lack of
efficacy (13 responses); duration of treatment (11 responses);
prompted by the patient asking to end treatment (10 responses);
noting an improvement in the patient’s symptoms (8 responses).
When the GPs were asked to estimate what proportion of their
patients who are on antidepressants approach them about stopping
their antidepressant medication, the mean result was 20%, although
the range was 2–100%. The mean result from psychiatrists was 23%
(range 0–100%), from the 24 out of 26 respondents who gave a
percentage.
The question on how they would typically go about withdrawing
a patient from antidepressants elicited the responses in Table 4
(respondents could tick all that applied).
The psychiatrist who responded ‘other’ stated that they would
‘Check the Maudsley guidance and follow that’.
When asked who they might consult/work with to support a
patient through withdrawal and staying off medication (this could
include professionals and non-professionals), the most common
answers from the GPs were: social prescriber, mentioned by 12
GPs; no other support needed (or available), mentioned by 10;
and consultant psychiatrist or other mental health counsellor,
each mentioned by 7. The main responses from the psychiatrists
were: patient/carer/family, mentioned by 13; GP, by 10; pharmacist
or care coordinator, each mentioned by 9; and other counsellor/
mental health practitioner, mentioned by 5.
As regards how often there is a discussion of potential with-
drawal symptoms with the patient before commencing antidepres-
sant treatment (Table 5), there was no statistical difference between
the two groups (P = 0.438).
The final question allowed for free-text comments on anti-
depressant withdrawal, to which nine GPs and ten psychiatrists
responded. Three GPs perceived that severe withdrawal was not a
problem in their experience (these GPs scored the severity of with-
drawal symptoms as 3, 4 and 5). Two other GPs noted that patients
often stop taking antidepressants when they feel better, often
without consulting their doctor.
Discussion
This small study looked to understand a number of issues related to
the withdrawal of antidepressants against a background of contro-
versy and fierce debate on the benefits and harms of this class of
medicine.11 It is a study that involved a full ecosystem of mental
health management, i.e. primary and secondary care across a
single CCG and geographical area (Cornwall) that covers about
1% of the UK population. We found some differences and similar-
ities in views both within the two groups of healthcare professionals
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Fig. 1 Perceived severity of withdrawal symptoms, as reported by
general practitioners (GPs) (n = 42) and psychiatrists (n = 26).
Table 2 Perceived proportion of patients affected by withdrawal
symptoms, as reported by general practitioners (n = 42) and psychia-
trists (n = 26)
Proportion affected General practitioners, n (%) Psychiatrists, n (%)
0% 0 (0%) 0 (0%)
1–20% 9 (21%) 6 (23%)
21–40% 19 (45%) 8 (31%)
41–60% 8 (19%) 8 (31%)
61–80% 5 (12%) 4 (15%)
81–100% 1 (2%) 0 (0%)
Table 3 Main five reasons mentioned for ceasing treatment, as
reported by general practitioners (n = 38) and psychiatrists (n = 26)
Reasons General practitioners, n Psychiatrists, n
Duration of treatment 26 11
Patient request 9 10
Side-effects 8 21




Lack of efficacy 0 13
Professionals’ attitudes towards antidepressant withdrawal
3
Downloaded from https://www.cambridge.org/core. 22 Jun 2020 at 09:50:43, subject to the Cambridge Core terms of use.
Limitations
The relatively small sample (42 GP responses and 26 psychiatry
responses) means that there is a risk of type 2 error, and genuine
differences might be revealed by a larger sample. To address this
limitation, we hope to extend this study to the rest of the South
West of the UK. The current study has been a useful pilot.
We recognise the limitations with this small study undertaken
in just one geographical region and, for the GPs, with a self-selected
group of healthcare professionals. Cornwall is a predominantly
rural and White (99.5%). It is also one of the most deprived areas
not only of the UK but also of the European Union. Thus, it is pos-
sible that healthcare professionals working in different healthcare
systems may hold different views on this subject. Further studies
to cover wider areas of the UK would show whether these results
are reproducible.
We also used a survey that could have introduced biases such as
recall bias and answering tendencies. Triangulation with objective
assessments of patient management such as case-note audits
would have added to our characterisation of current practice.
Our questions were about withdrawal of antidepressants for any
indication and respondents may actually have different views on
severity or absence of withdrawal symptoms depending on the con-
dition being treated.
Main findings
A systematic review reported that, overall, seven out of ten studies
found that a large proportion of participants reported experiencing
antidepressant withdrawal symptoms for more than 2 weeks.1 This
is somewhat contrary to our findings. The majority of respondents
from both groups of our study thought that withdrawal symptoms
typically last between 1 and 4 weeks: 53% (22/42) of GPs and 69%
(18/26) of psychiatrists. However, a wide range of answers was
given. For example, the GPs perceived that withdrawal symptoms
could last typically for anywhere between a matter of days
(6 respondents (15%) suggested less than a week) to 4–6 months
(2 respondents (5%)), which was similar to the perceptions of
some of the psychiatrists. Only 14 (33%) of our GPs and 12 (46%)
of our psychiatrists considered that the proportion of people
affected by withdrawal symptoms is greater than 40%.
Incidence and severity of withdrawal symptoms
As well as the heated debate about the merits of antidepressants, it is
argued that another important discrepancy between the scientific lit-
erature and prevailing beliefs held by leading psychiatrists concerns
withdrawal symptoms on discontinuation of antidepressant medica-
tion.12 According to several studies, severe and persistent withdrawal
reactions affect up to 50% of antidepressant users. Others quote that
more than 50% of people who attempted to stop antidepressants
experienced withdrawal effects and nearly 50% of those experiencing
withdrawal effects described them as severe.1 Notably, in our study
the psychiatrists considered withdrawal effects to be more severe
than the GPs. It is possible that this is due to differences in patient
populations encountered by the two groups, with psychiatrists
perhaps more likely than GPs to encounter patients who have been
on antidepressants for longer periods of time, which could make
withdrawal symptoms worse. Also, relationships have been shown
between mental disorders and medical comorbidities,13 so it is pos-
sible that those with more severe mental disorders or more
complex needs (who are therefore more likely to need psychiatrist
input) could show more severe withdrawal symptoms owing to an
interplay with other medical needs.
Prescribing practices
In an analysis of 52 recorded primary care consultations for depres-
sion, anxiety and stress, patients resisted treatment because of
doubts about its efficacy based on previous experiences, fears
about dependency and/or side-effects, and concerns about attend-
ing group therapy.14 Historically, it was known than many patients
on longer-term courses of antidepressants were not being appropri-
ately reviewed.15 A study of Scottish GPs during 2014–2015 noted
that the lack of proactive medication reviews (e.g. patients only
present in crisis) contributed to further antidepressant prescribing
growth over time.16 Twenty-six (62%) of our GPs and 11 (42%)
of our psychiatrists indicated that duration of treatment would
make them consider withdrawal of treatment.
Patient support during withdrawal
It is interesting that 12 GPs (29%) identified a social prescriber as
someone with whom they would consult/work to support a
patient through withdrawal and staying off medication, yet the evi-
dence base for social prescribing is very limited. It is recognised that
there is a need to consider support for health professionals in the
management of antidepressant medication and discussions of dis-
continuation in particular.17
Nine (35%) psychiatrists said they would involve pharmacists
and have access to them, but GPs did not mention seeking help
from pharmacists. This could raise the suggestion of whether it
would be valuable to encourage involvement of community phar-
macists in antidepressant withdrawal that is managed by GPs.
A recent study showed the potential support that community phar-
macists could give to patients on antidepressants, such as by mon-
itoring adherence and efficacy of treatment.18
Patient advice on potential withdrawal symptoms
Approximately three-quarters of respondents claimed that they
always or usually provide information to patients about potential
antidepressant withdrawal symptoms before commencing them.
This is in sharp contrast to an online survey of a self-selected con-
venience sample of patients, mainly from Europe, North America
and Australasia, in which less than 1% replied that had been told
anything about withdrawal effects.19
Table 4 Methods used for withdrawing a patient from antidepressants,






Taper with reduced solid dose
formulation (tablets/capsules)
doses
39 (93%) 25 (96%)
Taper with liquid form 9 (21%) 5 (19%)
Complete immediate withdrawal 6 (14%) 0 (0%)
Switch to another antidepressant
drug first
1 (2%) 3 (12%)
Use another drug to alleviate
withdrawal symptoms
0 (0%) 5 (19%)
Other (please state) 0 (0%) 1 (4%)
Table 5 How often general practitioners (n = 42) and psychiatrists
(n = 26) said there was a discussion of potential withdrawal symptoms






Always 9 (21%) 10 (38%)
Usually 24 (57%) 9 (35%)
Sometimes 3 (7%) 4 (15%)
Rarely 6 (14%) 3 (12%)
Never 0 (0%) 0 (0%)
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Implications for the patient
Our co-author, K.A., a lived experience expert who helped design
the study and questionnaires, shares her perspective in response
to the results of this study:
‘This project highlights that there still remain gaps between
perceptions of clinicians to those of patients. It is my personal
experience and those who I represent that withdrawing from
antidepressants would be much longer lasting and have more
serious withdrawal effects than what has been reported clinic-
ally here. Personally, and I expect for many, it is a scary project
to undertake. There is a lack of resources and support available
to support person-centred withdrawal. I don’t recall ever being
warned by anyone treating me about withdrawal effects
beyond the generic message of don’t stop suddenly. The
study highlights that many of the concerns I have outlined
have not been objectively examined.’
Implications for practice
One of the key findings of this study is that roughly 75% of psychia-
trists and GPs say they always or usually warn patients about with-
drawal side-effects, but patient surveys say that only 1% are warned.
This could be because clinicians are rapidly changing as awareness is
growing, which would be positive, or because there is a communi-
cation gap and the message is not clear enough. The mismatch
between the findings of our study and previous patient surveys
could also mean that some patients who are told about withdrawal
symptoms simply do not recall this. Both of possible negative expla-
nations suggest a need to encourage more GPs and psychiatrists to
inform patients of potential withdrawal effects and to do this in a
way that patients will remember.
Implications for policy
The results highlight that a proportion of psychiatrists involve phar-
macists when withdrawing a patient from antidepressants, but GPs
do not. Encouraging involvement of community pharmacists to
support GPs in doing this may be a useful source of support.
Implications for research
Antidepressant withdrawal is a serious public health concern that war-
rants more research and adequate appraisal by academic psychiatry.12
It is interesting to note such a high variation in responses from all par-
ticipants. The diversity of responses reflects the wide variation in
results from research studies. This shows a need formore reproducible
studies to be carried out into the patient experience of antidepressant
withdrawal. We suggest that future studies exploring this topic should
carefully consider their methodology to make it as representative as
possible. This means that a more precise impression could be given
of the proportion of patients who are affected by antidepressant with-
drawal, how often the symptoms typically last and so on. This could
also include, for example, identifying patient groups who are more
at risk of severe withdrawal symptoms. This could inform future
guidelines to make them more specific, so that GPs and psychiatrists
are able to provide more consistent evidence-based advice and man-
agement to patients, which could improve patient outcomes.
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Appendix
Edited summary of topics covered by the questions asked in the
study:
(a) duration of withdrawal symptoms
(b) severity of withdrawal symptoms
(c) proportion of people affected by withdrawal symptoms when
stopping antidepressants
(d) prompts for stopping antidepressants
(e) proportion of patients who approach the respondent about
stopping antidepressants
(f) how antidepressants are typically withdrawn
(g) who might be consulted/worked with to support a patient to
withdraw and stay off antidepressants
(h) frequency of discussion of withdrawal symptoms with patients
before commencing antidepressant treatment
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